Spero Therapeutics Inc.(SPRO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SPRO Spero Therapeutics Inc.

交易中 08-18 12:56:47 EDT

1.19

+0.00

-0.42%

最高1.20	最低1.18	成交量23.48万
今开1.20	昨收1.19	日振幅2.10%
总市值6,901万	流通市值5,402万	总股本5,823万
成交额27.94万	换手率0.52%	流通股本4,559万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SPRO","market":"US","secType":"STK","nameCN":"Spero Therapeutics Inc.","latestPrice":1.185,"timestamp":1787072193166,"preClose":1.19,"halted":0,"volume":234777,"delay":0,"changeRate":-0.004201680672268818,"floatShares":45585503,"shares":58234827,"eps":0.129013,"marketStatus":"交易中","change":-0.005,"latestTime":"08-18 12:56:47 EDT","open":1.2,"high":1.2,"low":1.175,"amount":279419.7995946,"amplitude":0.021008,"askPrice":1.19,"askSize":1832,"bidPrice":1.18,"bidSize":3268,"shortable":3,"etf":0,"ttmEps":0.129013,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787083200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1509595200000,"exchange":"NASDAQ","adjPreClose":1.19,"preHourTrading":{"tag":"盘前","latestPrice":1.1802,"preClose":1.19,"latestTime":"08:24 EDT","volume":37,"amount":43.682000200000004,"timestamp":1787055856344,"change":-0.0098,"changeRate":-0.008235,"amplitude":0.017899},"postHourTrading":{"tag":"盘后","latestPrice":1.1831,"preClose":1.19,"latestTime":"19:30 EDT","volume":8719,"amount":10318.0566,"timestamp":1787009404304,"change":-0.0069,"changeRate":-0.005798,"amplitude":0.014202},"volumeRatio":0.636436,"impliedVol":0.3916,"impliedVolPercentile":0.0677},"requestUrl":"/m/hq/s/SPRO","defaultTab":"news","newsList":[{"id":"1155043513","title":"Spero Therapeutics 将于2026年8月12日公布第二季度财报并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1155043513","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155043513?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:02","pubTimestamp":1785873735,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. 宣布，计划于2026年8月12日发布公司第二季度财务业绩，并同期向市场提供最新的业务运营动态。这一举措，无疑将为投资者带来关于公司近期发展轨迹的关键洞察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122938039","title":"Spero Therapeutics - Hcrx将获得源自葛兰素史克应付Spero款项的季度本金与利息支付，直至贷款偿清","url":"https://stock-news.laohu8.com/highlight/detail?id=1122938039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122938039?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:06","pubTimestamp":1784023566,"startTime":"0","endTime":"0","summary":"Spero Therapeutics - Hcrx将获得源自葛兰素史克应付Spero款项的季度本金与利息支付，直至贷款偿清。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935042215.USD","LU1791807156.HKD","PSP","LU1668664300.SGD","LU0130102774.USD","BK4139","LU1670756490.USD","SG9999013999.USD","LU0980610538.SGD","SGXZ57979304.SGD","BK4135","SG9999001176.SGD","LU1064927863.SGD","SPRO","LU0106831901.USD","LU1935043536.SGD","LU2468319806.SGD","LU0985481810.HKD","LU1309081286.SGD","LU0987226296.USD","LU1645745479.HKD","LU0289739699.SGD","LU0203347892.USD","LU1935042991.SGD","LU0971552673.USD","LU1302929846.USD","LU1487256676.USD","LU0109981661.USD","LU0225284248.USD","LU1202635105.USD","LU0971552830.HKD","IE00BGHQF748.EUR","BK4585","BK4588","IE00BQJZX424.USD","LU0211331839.USD","LU0306807586.USD","LU0648001328.SGD","LU1935043023.USD","LU0058720904.USD","LU1400636574.HKD","LU1035777561.USD","LU0306806265.USD","IE00BWDBJ516.SGD","BK5011","LU0225283273.USD","LU0161305163.EUR","KKR","LU1400636657.SGD","LU2089984988.USD","LU0203345920.USD","LU0225771236.USD","LBO","LU1228905037.USD","LU1400636491.USD","LU0557290698.USD","LU1098665638.USD","LU1015430645.USD","IE0034235071.USD","LU1046248800.SGD","GSK.UK","LU1935042488.USD","LU1201861249.SGD","IE00B3T34201.USD","LU0321505868.SGD","IE00B64PRP62.GBP","LU1481600234.SGD","IE00B3QW5Z07.USD","LU2646069778.SGD","LU1228905540.USD","LU1481599808.USD","LU0575583348.USD","LU0321505439.SGD","LU1983299246.USD","LU0545562505.USD","SG9999001176.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149400024","title":"Spero Therapeutics 与 Hcrx 达成协议 后者将支付1.05亿美元获取来自葛兰素史克的Utebzi付款权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1149400024","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149400024?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:05","pubTimestamp":1784023515,"startTime":"0","endTime":"0","summary":"根据协议，Hcrx将在交易完成时向Spero Therapeutics支付1.05亿美元，以获取从葛兰素史克收取Utebzi相关付款的权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935042215.USD","LU1791807156.HKD","PSP","LU1668664300.SGD","LU0130102774.USD","BK4139","LU1670756490.USD","SG9999013999.USD","LU0980610538.SGD","SGXZ57979304.SGD","BK4135","SG9999001176.SGD","LU1064927863.SGD","SPRO","LU0106831901.USD","LU1935043536.SGD","LU2468319806.SGD","LU0985481810.HKD","LU1309081286.SGD","LU0987226296.USD","LU1645745479.HKD","LU0289739699.SGD","LU0203347892.USD","LU1935042991.SGD","LU0971552673.USD","LU1302929846.USD","LU1487256676.USD","LU0109981661.USD","LU0225284248.USD","LU1202635105.USD","LU0971552830.HKD","IE00BGHQF748.EUR","BK4585","BK4588","IE00BQJZX424.USD","LU0211331839.USD","LU0306807586.USD","LU0648001328.SGD","LU1935043023.USD","LU0058720904.USD","LU1400636574.HKD","LU1035777561.USD","LU0306806265.USD","IE00BWDBJ516.SGD","BK5011","LU0225283273.USD","LU0161305163.EUR","KKR","LU1400636657.SGD","LU2089984988.USD","LU0203345920.USD","LU0225771236.USD","LBO","LU1228905037.USD","LU1400636491.USD","LU0557290698.USD","LU1098665638.USD","LU1015430645.USD","IE0034235071.USD","LU1046248800.SGD","GSK.UK","LU1935042488.USD","LU1201861249.SGD","IE00B3T34201.USD","LU0321505868.SGD","IE00B64PRP62.GBP","LU1481600234.SGD","IE00B3QW5Z07.USD","LU2646069778.SGD","LU1228905540.USD","LU1481599808.USD","LU0575583348.USD","LU0321505439.SGD","LU1983299246.USD","LU0545562505.USD","SG9999001176.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191493105","title":"Spero Therapeutics 在偿还GSK款项后将保留后续Utebzi销售相关付款的35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191493105","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191493105?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:04","pubTimestamp":1784023445,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. 宣布，在完成对葛兰素史克（GSK）相关款项的偿还后，公司将有权保留未来与抗生素Utebzi销售相关的后续付款中的35%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSP","KKR","LU1935042991.SGD","LU1935042488.USD","LU0106831901.USD","LU0130102774.USD","LU1935043536.SGD","LU0980610538.SGD","IE00BGHQF748.EUR","BK4139","BK4585","LU0314104364.USD","LU1935042215.USD","SPRO","IE00B64PRP62.GBP","BK4588","LU1791807156.HKD","LU1935043023.USD","LU0648001328.SGD","IE00B3QW5Z07.USD","LU1201861249.SGD","BK4135","LBO","LU1668664300.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193620961","title":"Spero Therapeutics宣布获得1.05亿美元基于Utebzi里程碑与特许权使用费的非追索、非摊薄融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1193620961","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193620961?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:03","pubTimestamp":1784023396,"startTime":"0","endTime":"0","summary":"Spero Therapeutics宣布，已成功获得一笔高达1.05亿美元的非追索、非摊薄融资。这笔资金由公司旗下产品Utebzi未来的部分里程碑付款及特许权使用费收入提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU0314104364.USD","LU0980610538.SGD","BK4135","LU1935042488.USD","LBO","SPRO","LU0130102774.USD","IE00B64PRP62.GBP","PSP","LU1935043536.SGD","IE00BGHQF748.EUR","BK4139","LU0648001328.SGD","LU1201861249.SGD","LU1935042215.USD","LU1935042991.SGD","BK4585","BK4588","KKR","IE00B3QW5Z07.USD","LU1935043023.USD","LU1791807156.HKD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130460477","title":"Spero与信达生物合作，将于2027年初在中国启动干燥综合征二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1130460477","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130460477?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:02","pubTimestamp":1784023345,"startTime":"0","endTime":"0","summary":"斯佩罗治疗公司与信达生物宣布，双方将合作推进一项针对干燥综合征的创新疗法临床研究。根据最新规划，该疗法的二期临床试验预计于2027年初在中国正式启动。此次合作结合了斯佩罗治疗公司在感染性疾病与炎症领域的技术积累，以及信达生物在中国市场的临床开发与商业化优势。若试验进展顺利，该药物有望为中国的干燥综合征患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRO","LU2097828474.EUR","HK0000165453.HKD","LU2097828714.EUR","BK1589","01801","BK1161","BK1583","LU1969619763.USD","LU2097828557.USD","LU2097828631.EUR","BK4139","LU2242644610.SGD","LU0455707207.USD","LU0502904849.HKD","LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159666906","title":"信达生物与Spero Therapeutics就Ibi355 (SP001)达成独家授权协议，该第三代抗CD40L抗体已准备进入二期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1159666906","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159666906?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:01","pubTimestamp":1784023292,"startTime":"0","endTime":"0","summary":"信达生物与Spero Therapeutics Inc.共同宣布，双方已就Ibi355（亦称为SP001）达成一项独家授权协议。该候选药物是一款已准备进入二期临床试验阶段的第三代抗CD40L抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU0502904849.HKD","LU2097828474.EUR","LU2097828631.EUR","LU2488822045.USD","BK1583","LU0455707207.USD","BK4139","BK1161","LU2328871848.SGD","LU2097828805.USD","LU2242644610.SGD","HK0000165453.HKD","LU2097828557.USD","KURE","01801","SPRO","LU1969619763.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183262535","title":"GSK宣布美国FDA批准cUTI口服抗生素特比培南","url":"https://stock-news.laohu8.com/highlight/detail?id=1183262535","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183262535?lang=zh_cn&edition=full","pubTime":"2026-06-17 23:27","pubTimestamp":1781710047,"startTime":"0","endTime":"0","summary":"葛兰素史克（GSK）宣布，其用于治疗复杂性尿路感染（cUTI）的口服抗生素特比培南已获得美国食品药品监督管理局（FDA）的批准。该药物预计将于2026年底前在美国上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157736208","title":"Spero Therapeutics一季度运营支出达779.6万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157736208","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157736208?lang=zh_cn&edition=full","pubTime":"2026-05-14 04:20","pubTimestamp":1778703601,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Inc. 最新公布的财务数据显示，该公司第一季度运营支出为779.6万美元。与此同时，其运营亏损为753.8万美元。这一数据揭示了该生物技术公司在报告期内的财务运营状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119642553","title":"Spero Therapeutics将于2026年3月26日公布2025财年第四季度及全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1119642553","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119642553?lang=zh_cn&edition=full","pubTime":"2026-03-19 04:07","pubTimestamp":1773864458,"startTime":"0","endTime":"0","summary":"生物制药公司Spero Therapeutics宣布，将于2026年3月26日公布2025财年第四季度及全年财务业绩，并同步举行电话会议讨论业务进展。此次财报将披露公司在抗菌药物研发管线的关键运营指标、现金流状况及临床项目里程碑。Spero Therapeutics专注于开发应对多重耐药菌感染的创新疗法，核心产品tebipenem HBr作为口服碳青霉烯类抗生素，针对复杂性尿路感染已进入商业化准备阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516323416","title":"Spero Therapeutics, Inc.盘中异动 股价大涨5.81%报0.821美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516323416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516323416?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:35","pubTimestamp":1741012558,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时35分，Spero Therapeutics, Inc.股票出现异动，股价大幅拉升5.81%。截至发稿，该股报0.821美元/股，成交量1.3081万股，换手率0.02%，振幅1.93%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为48.17%、32.30%、29.61%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Pliant Therapeutics, Inc.，振幅分别为21.22%、19.25%、16.66%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223558abe634c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223558abe634c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRO","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514775240","title":"Spero Therapeutics, Inc.盘中异动 早盘股价大跌6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514775240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514775240?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:23","pubTimestamp":1740414181,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日00时23分，Spero Therapeutics, Inc.股票出现异动，股价大幅下跌6.03%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Pepgen Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为244.73%、110.91%、34.18%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Celularity Inc C/Wts 16/07/2026 ，振幅分别为162.04%、55.69%、54.86%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225002301962eb1cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225002301962eb1cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRO","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510380652","title":"Spero Therapeutics, Inc.盘中异动 早盘股价大涨5.47%报0.839美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510380652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510380652?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:41","pubTimestamp":1739284897,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时41分，Spero Therapeutics, Inc.股票出现波动，股价快速拉升5.47%。截至发稿，该股报0.839美元/股，成交量3769股，换手率0.01%，振幅1.13%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.30%。其相关个股中，Dominari Holdings Inc.、Ocean Biomedical, Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2246.85%、594.59%、232.24%，振幅较大的相关个股有Ocean Biomedical, Inc.、In8Bio, Inc.、Dominari Holdings Inc.，振幅分别为33.04%、31.80%、29.38%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241389881bf0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112241389881bf0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRO","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509974729","title":"Spero Therapeutics, Inc.盘中异动 快速跳水5.02%报0.820美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509974729","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509974729?lang=zh_cn&edition=full","pubTime":"2025-02-08 00:55","pubTimestamp":1738947300,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日00时55分，Spero Therapeutics, Inc.股票出现异动，股价急速跳水5.02%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。其相关个股中，Conduit Pharmaceuticals Inc.、Nutriband Inc C/Wts 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为5352.11%、168.60%、102.84%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为130.43%、67.10%、53.38%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208005501987dc70d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208005501987dc70d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509412496","title":"Spero Therapeutics, Inc.盘中异动 下午盘股价大跌5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509412496","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509412496?lang=zh_cn&edition=full","pubTime":"2025-02-05 04:25","pubTimestamp":1738700748,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日04时25分，Spero Therapeutics, Inc.股票出现波动，股价快速下跌5.97%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.28%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Mink Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为1952.22%、989.90%、587.97%，振幅较大的相关个股有Azitra Inc、Omega Therapeutics, Inc.、Mink Therapeutics, Inc.，振幅分别为123.99%、59.42%、58.27%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205042549987a802a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205042549987a802a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRO","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508914184","title":"Spero Therapeutics, Inc.盘中异动 股价大跌5.44%报0.810美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508914184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508914184?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:47","pubTimestamp":1738594055,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时47分，Spero Therapeutics, Inc.股票出现波动，股价大幅跳水5.44%。截至发稿，该股报0.810美元/股，成交量3.0259万股，换手率0.06%，振幅1.82%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为416.32%、352.70%、216.64%，振幅较大的相关个股有Hcw Biologics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Invivyd, Inc.，振幅分别为82.67%、50.76%、35.62%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224735abc10b4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224735abc10b4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SPRO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505527014","title":"Spero Therapeutics, Inc.盘中异动 股价大涨5.26%报0.920美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505527014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505527014?lang=zh_cn&edition=full","pubTime":"2025-01-23 22:42","pubTimestamp":1737643377,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日22时42分，Spero Therapeutics, Inc.股票出现波动，股价大幅拉升5.26%。截至发稿，该股报0.920美元/股，成交量2162股，换手率0.00%，振幅0.00%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Hepion Pharmaceuticals, Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Exicure, Inc.涨幅较大，Hepion Pharmaceuticals, Inc.、Quoin Pharmaceuticals Ltd、Vigil Neuroscience, Inc.较为活跃，换手率分别为2213.85%、518.29%、40.11%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Nutriband Inc C/Wts 、Exicure, Inc.，振幅分别为54.22%、49.73%、29.32%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123224258abb5fd66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123224258abb5fd66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504410189","title":"Spero Therapeutics, Inc.盘中异动 下午盘股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504410189","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504410189?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:57","pubTimestamp":1737053834,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日02时57分，Spero Therapeutics, Inc.股票出现波动，股价急速跳水5.26%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.61%。其相关个股中，Surrozen Inc C/Wts 01/08/2031 、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Aeon Biopharma, Inc.涨幅较大，Aditxt, Inc.、Phio Pharmaceuticals Corp.、Aeon Biopharma, Inc.较为活跃，换手率分别为1919.58%、1179.99%、732.05%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Aeon Biopharma, Inc.，振幅分别为152.94%、131.33%、104.84%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117025715abad88ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117025715abad88ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRO","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503642773","title":"Spero Therapeutics, Inc.盘中异动 早盘股价大跌5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503642773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503642773?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951533,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Spero Therapeutics, Inc.股票出现异动，股价大幅跳水5.56%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。其相关个股中，Monte Rosa Therapeutics, Inc.、Exicure, Inc.、Generation Bio Co.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为185.03%、52.76%、35.39%，振幅较大的相关个股有Onconetix, Inc.、Klotho Neurosciences, Inc.、Vincerx Pharma, Inc.，振幅分别为12.28%、12.00%、10.72%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152232139604b411&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152232139604b411&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRO","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503558535","title":"Spero Therapeutics, Inc.盘中异动 下午盘快速下挫5.10%报0.930美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503558535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503558535?lang=zh_cn&edition=full","pubTime":"2025-01-14 04:14","pubTimestamp":1736799277,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日04时14分，Spero Therapeutics, Inc.股票出现波动，股价大幅跳水5.10%。截至发稿，该股报0.930美元/股，成交量11.9539万股，换手率0.22%，振幅7.14%。Spero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.较为活跃，换手率分别为15456.65%、7913.87%、842.39%，振幅较大的相关个股有Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.，振幅分别为336.09%、227.48%、201.86%。Spero Therapeutics, Inc.公司简介：Spero Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114041438aba98167&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114041438aba98167&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SPRO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sperotherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0325},{"period":"1month","weight":-0.2468},{"period":"3month","weight":-0.5405},{"period":"6month","weight":-0.4893},{"period":"1year","weight":-0.377},{"period":"ytd","weight":-0.4893}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0395},{"period":"3month","weight":0.0531},{"period":"6month","weight":0.1259},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.1331}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spero Therapeutics, Inc.于2013年12月根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，专注于识别和开发罕见疾病和高未满足需求疾病的新疗法。该公司的临床阶段候选产品teipenem HBr已完成第二项3期试验，有潜力成为首个口服碳青霉烯类药物，用于治疗由某些微生物引起的复杂尿路感染成人患者，包括肾盂肾炎。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.027619},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.041579},{"month":3,"riseRate":0.444444,"avgChangeRate":0.002736},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.023649},{"month":5,"riseRate":0.444444,"avgChangeRate":0.227023},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.019322},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.107268},{"month":8,"riseRate":0.333333,"avgChangeRate":0.024825},{"month":9,"riseRate":0.375,"avgChangeRate":0.142637},{"month":10,"riseRate":0.375,"avgChangeRate":0.001197},{"month":11,"riseRate":0.5,"avgChangeRate":0.018182},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.012412}],"exchange":"NASDAQ","name":"Spero Therapeutics Inc.","nameEN":"Spero Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spero Therapeutics Inc.(SPRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Spero Therapeutics Inc.(SPRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Spero Therapeutics Inc.,SPRO,Spero Therapeutics Inc.股票,Spero Therapeutics Inc.股票老虎,Spero Therapeutics Inc.股票老虎国际,Spero Therapeutics Inc.行情,Spero Therapeutics Inc.股票行情,Spero Therapeutics Inc.股价,Spero Therapeutics Inc.股市,Spero Therapeutics Inc.股票价格,Spero Therapeutics Inc.股票交易,Spero Therapeutics Inc.股票购买,Spero Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spero Therapeutics Inc.(SPRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Spero Therapeutics Inc.(SPRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}